Drug Profile

Norepinephrine Bitartrate - Nevakar Injectables

Alternative Names: Norepinephrine Bitartrate in Sodium Chloride injection - Nevakar Injectables; Premix Norepinephrine Bitartrate

Latest Information Update: 30 Jun 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Nevakar
Class Antihypotensives; Cardiotonics; Catecholamines; Vasoconstrictors
Mechanism of Action Alpha adrenergic receptor agonists; Beta adrenergic receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

04 May 2023 Long Grove Pharmaceuticals in-licenses Norepinephrine in 0.9% Sodium Chloride premix formulation from Nevakar Injectables
04 May 2023 Early research in Hypotension in USA (IV)
04 May 2023 Nevakar Injectables, received FDA clearance for norepinephrine bitartrate in 0.9% sodium chloride injection

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com